Homocysteine and risk of stroke

Journal of Cardiovascular Risk

Volumn 6, Issue 4, 1999, Pages 235-240

  Perry, Ivan J ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Epidemiological study; Homocysteine; Stroke

Indexed keywords

HOMOCYSTEINE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE;

ATHEROGENIC DIET; CAROTID ARTERY OBSTRUCTION; CIGARETTE SMOKING; HOMOCYSTINURIA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; AGE; ARTERIAL WALL THICKNESS; BLOOD LEVEL; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIETARY INTAKE; HETEROZYGOSITY; HOMOCYSTEINE BLOOD LEVEL; HOMOZYGOSITY; HYPERHOMOCYSTEINEMIA; HYPERTENSION; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; SMOKING;

EID: 0032874965     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1177/204748739900600408     Document Type: Review

References (37)

1. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1-31. A classic paper on natural history of severe congenital homocysteinuria.
2. Mudd SH, Levy HL, Skovby F (editors). Disorders of transulfuration. New York: McGraw-Hill; 1995.
3. 6 as key determinants of hyperhomocysteinaomia among the elderly. Compliance with current nutritional guidelines for this age-group is not necessarily associated with normal levels of homocysteine.
4. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular disease risk? N Engl J Med 1995; 332:328-329.
5. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis DB Jr (editor): Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992. pp. 183-236.
6. Boushey CJ, Beresford SAA, Omenn GS, Motolsky AG. A quantative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057. A definitive meta-analysis of studies, published up to June 1994, addressing associations between homocysteine and coronary artery disease, cerebrovascular disease and peripheral vascular disease. It includes a good discussion of public health implications of the findings, with particular reference to folate supplementation.
7. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762.
8. Cattaneo M. Hyperhomocysteinaemia. Vessels 1997; 3:16-21.
9. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Storkosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate roductase. Am J Hum Genet 1988; 42:414-421.
10. Ma JSM, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94:2410-2416.
11. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenotetrahydrofolate reductase [letter]. Nat Genet 1995; 10:111-113.
12. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236:633-641.
13. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274:1526-1533. Large cross-sectional study, providing good data on associations between homocysteine and established cardiovascular disease risk factors.
14. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67:263-270.
15. Phillips AN, Smith GD. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991; 44:1223-1231.
16. Boers GHJ. Hyperhomocysteinemia: a newly recognised risk factor for vascular disease. Neth J Med 1994; 45:34-41.
17. Boers GH. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78:520-522.
18. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277:1775-1781. Major case-control study from the European Concerted Action project. The study was based in 19 centres in nine European countries and recruited a total of 750 cases of atherosclerotic vascular disease (cardiac cerebral and peripheral) and 800 controls of both sexes, younger than 60 years. The study reports positive findings on associations between homocysteine and vascular end-points and provides detailed exploration of interactions between homocysteine and established risk factors.
19. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9-19.
20. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25:1924-1930.
21. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97:437-443.
22. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87:1107-1113.
23. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 1997; 242:339-347.
24. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291. This study provides data suggesting a continuous graded association between plasma homocysteine concentrations and carotid artery disease.
25. Perry I, Refsum H, Morris R, Ebrahim S, Ueland P, Shaper A. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395-1398. A nested case-control study within the British Regional Heart Study cohort, addressing the association between serum total homocysteine and risk of stroke. The findings suggest a continuous association between serum homocysteine and risk of stroke without an obvious threshold.
26. Perry IJ. Serum total homocysteine concentration and risk of stroke [letter]. Lancet 1996; 348:1526.
27. Bots ML, Witteman JCM, Hoes AW, Koudstaal PJ, Grobbee DE. Homocysteine and risk of cardiovascular disease in the elderly. The Rotterdam Study [abstract]. Can J Cardiol 1997; 13 (suppl B): 150B.
28. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 1995; 26:1166-1170.
29. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236:603-617.
30. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236.
31. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-1050. Good review of recent work on homocysteine and vascular disease, with a short, but comprehensive overview of current hypotheses on the pathophysiological mechanisms of hyperhomocysteinaemia.
32. Kostulas K, Crisby M, Huang WX, Lannfelt L, Hagenfeldt L, Eggertsen G, et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest 1998; 28:285-289.
33. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28:1739-1743.
34. Brattstrom L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease [letter]. Circulation 1997; 96:3805-3807.
35. Cattaneo MTM, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylinetetrahydrofolate reductase gene (C6771) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V: Q506) [abstract]. Blood 1996; 10 (suppl 1):285a.
36. Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35- year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C. Metabolism 1997; 46:1470-1472.
37. Hornberger J. A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. Am J Public Health 1998; 88:61-67.